AME

Business profile & competitive position

AMETEK, Inc. is classified in the Industrials sector, specifically the Electrical Equipment & Parts industry. In practice, the company is a global manufacturer of electronic instruments and electromechanical devices, organized into two operating groups: Electronic Instruments (EIG) and Electromechanical (EMG). EIG designs and manufactures advanced analytical, test and measurement instruments sold into the process, aerospace, power and industrial markets. EMG supplies precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals and electrical interconnects for aerospace and defense, medical, automation and other industrial end markets.

The reported 20.0% net margin and 14.5% return on equity provide the quantitative backbone for assessing competitive strength. A 20.0% net margin is well above what is typical for broad-based industrial manufacturers, suggesting that AMETEK's products carry meaningful pricing power, that its customers face high switching costs, or both. The 14.5% ROE indicates that the company is converting equity capital into profits at a level that generally outperforms the median industrial. Those figures, combined with beta of 1.00, portray a high-quality, profitable business whose stock volatility roughly matches the overall market.

Financial posture

AMETEK carries a market capitalization of $53.8 billion and trades at a trailing P/E ratio of 34.2. That multiple sits at a clear premium to many industrial conglomerates, implying that the market is pricing in sustained earnings growth and high returns on capital. The premium is at least partly justified by the company's 20.0% net margin and 14.5% ROE, as well as its record of converting specialty-engineering demand into利润able cash flow.

At the current snapshot, the stock is priced at $234.77, with a 50-day exponential moving average of $241.39 and an RSI of 38.3, which places it near the lower edge of the neutral range without being deeply oversold. The beta of 1.00 indicates the equity's systematic risk is roughly in line with the broader market, so macro-driven selloffs or rallies in the Industrials sector tend to move the stock by an average amount.

Strategic priorities & outlook

AMETEK's most recent 10-K filing outlines a clear set of operational priorities centered on the AMETEK Growth Model, which targets high-single-digit annual sales growth, double-digit annual EPS growth, strong cash flow generation and a superior return on total capital. Operational Excellence is the execution layer, relying on lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization and artificial intelligence.

Acquisitions remain central to the strategy. From 2021 through December 31, 2025, AMETEK closed 15 acquisitions representing approximately $1.8 billion in annualized sales. In 2025 alone, the company spent $933.2 million in cash, net of cash acquired, to purchase Kern and FARO Technologies. The company also continues to expand globally and in emerging markets, maintaining best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico and Serbia to stay close to customers and support international growth. In 2025, AMETEK posted net sales of $7,401.1 million, up 6.6% from 2024, and diluted EPS of $6.40, up 7.9%, alongside record operating income, net income, orders and backlog.

Macro & geopolitical exposure

Because AMETEK sits in the Electrical Equipment & Parts industry and serves aerospace, defense, medical, power, process and automation markets, its exposures are broad. Defense exposure means sensitivity to U.S. and allied military budgets, export controls and foreign military sales regulations. Medical-components sales are affected by healthcare capital spending, regulatory compliance and hospital capital budgets. Industrial test and measurement demand generally tracks manufacturing activity, capital investment cycles and capital-equipment lead times.

Geographic revenue concentration matters as well. In 2025, 52% of EIG net sales and 42% of EMG net sales went to customers outside the United States, making currency translation and regional growth relevant. With best-cost manufacturing footprints in China, Czechia, Malaysia, Mexico and Serbia, the company is also exposed to tariffs, trade-policy shifts, logistics costs and supply-chain localization pressures.

Recent developments

Recent headlines have reinforced the company's acquisition focus and quality perception. On August 26, 2026, AMETEK completed its acquisition of Indicor Instrumentation, continuing the M&A-driven growth strategy (prnewswire.com). On August 21, 2026, Zacks upgraded AMETEK to Buy (zacks.com), and the same day listed it among "5 High ROE Stocks to Buy as Markets Sway on Intense Volatility." Earlier, on August 10, 2026, AMETEK was featured in a Zacks piece on "Top 3D Printing Stocks to Buy for Strong Long-Term Potential," likely reflecting the addition of FARO's 3D measurement and imaging capabilities. These items do not independently justify an investment case, but they do illustrate that recent news flow has centered on M&A execution and return-on-equity recognition.

Earnings behavior & post-earnings drift

AMETEK has been one of the most consistent earnings beaters in its coverage universe. Over the last eight reported quarters, it beat estimates in every quarter (8/8, or 100%), with an average earnings surprise of 4%. Despite the perfect beat rate, the average 5-day price move following those reports was only 0.46%, classified as "flat" drift. That combination—reliable beats but muted follow-through—suggests the good news is frequently embedded in the stock ahead of the release.

The four most recent quarters confirm the pattern. On August 4, 2026, AMETEK reported EPS of $2.09 versus the $1.99 estimate, a 5% surprise, and the stock rose 0.28% the next day and 0.89% over five days. On April 30, 2026, EPS of $1.97 beat the $1.90 estimate by 3.7%, yet the stock fell 2.13% the next day and 0.33% over five days. On February 3, 2026, EPS of $2.01 beat $1.94 by 3.6%, with a next-day decline of 0.48% but a five-day gain of 1.83%. On October 30, 2025, EPS of $1.89 beat $1.76 by 7.4%, producing a next-day jump of 1.91% but a five-day decline of 0.54%. The next report is scheduled for October 29, 2026, before the market open, with the unofficial consensus EPS estimate at $2.11.

For a deeper dive into how sell-side and institutional analysts are currently weighing AMETEK's valuation, earnings setup and risk factors, readers can look at the full institutional verdict on the ticker page.